Related Experiment Video

Updated: May 30, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Trastuzumab in HER2-positive metastatic gastric cancer: profile report

Jamie D Croxtall1, Kate McKeage

  • 1Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|August 6, 2011
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Experiment Videos

Last Updated: May 30, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Drugs & therapy perspectives : for rational drug selection and use·2019

Risankizumab: First Global Approval.

Drugs·2019

Ravulizumab: First Global Approval.

Drugs·2019

Ginkgo biloba extract EGb 761® in the symptomatic treatment of mild-to-moderate dementia: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Drugs & therapy perspectives : for rational drug selection and use·2018

Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.

Clinical drug investigation·2017

From Reflection to Implementation: Tailored Clinical Development of a Pembrolizumab Biosimilar Candidate.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

HLX11: A Pertuzumab Biosimilar.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Beyond the Prevention of Anti-drug Antibody Formation with Uricase Therapy: Mechanistic Roles of DMARDs in Modifying Gout Flare Risk.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Biologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Biosimilars: A Virtuous Cycle of Sustainability and Innovation.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us